PTC Therapeutics, Inc. insider Pierre Gravier reported a change in beneficial ownership of PTC Therapeutics common stock tied to the vesting of restricted stock units and an automatic tax-withholding sale. On July 14, 2026, Gravier sold 3,494 shares of PTC Therapeutics common stock at $80.35 per share, for aggregate proceeds of approximately $280,743. The sale was an automatic “sell-to-cover” transaction, made pursuant to an irrevocable election entered into when the underlying equity award was accepted. The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary open-market sale. The tax-related sale was connected to the vesting of 6,500 RSUs from a July 13, 2023 grant that originally covered 26,000 RSUs. After the automatic sale of 3,494 shares to cover taxes, the vesting would have left Gravier with a net increase of 3,006 shares from that vesting event, before considering any other holdings or transactions. The filing also notes that Gravier’s reported common stock ownership includes 162 shares acquired through PTC Therapeutics’ employee stock purchase plan for the period ended June 30, 2026. The provided filing text does not state Gravier’s total beneficial ownership after the reported transaction. The Form 4 was signed on July 16, 2026, by Avraham S. Adler as attorney-in-fact for Gravier. The reported activity reflects routine equity compensation administration: RSUs vested, shares were issued, and a portion was automatically sold to cover required taxes.